Loading candles…
Eris Lifesciences Ltd operates in the pharmaceutical industry in India, focusing on the manufacture and marketing of domestic pharmaceutical formulations. The company’s portfolio includes products in cardiology, diabetes, gastroenterology, dermatology, as well as medical aesthetics and injectables. Its business model centers on a pure-play domestic formulations strategy supported by a field force that engages with super-specialist and specialist doctors. Eris Lifesciences has established a strong market position in the chronic segment, which constitutes a significant portion of its revenue. There is no publicly available information regarding its incorporation year, founders, key management, subsidiaries, or stock exchange listings.
This page is a live market overview for ERIS LIFESCIENCES LIMITED (ERIS) on the NSE. As a listed security, ERIS LIFESCIENCES LIMITED is tracked in the Healthcare segment of the Indian cash market and is widely followed for price discovery, liquidity and sector exposure. Use this overview to review price action, session ranges and derivatives context for ERIS before placing trades on tick2trade.
As of the latest feed, ERIS last traded at ₹1,382.4 on NSE, down ₹0.5 (0.04%) from the previous close of ₹1,382.9. Today's session range is ₹1,370.2 – ₹1,395, against a 52-week band of ₹1,200 – ₹1,855.6. Traded volume today stands at 40.49K shares.
The overview consolidates an interactive price chart with multiple time ranges, recent market headlines, upcoming corporate events for ERIS in one place so you do not need multiple screens during the session. Day and 52-week ranges help you judge whether ERIS is trading near support, resistance or the middle of its recent band. Volume and depth, when available, add context on how aggressively the name is being bought or sold.
Equity overview pages are built for investors who want a single reference for ERIS LIFESCIENCES LIMITED before reading news, checking results or sizing a position. Corporate events and headlines in the side column surface catalysts that may explain sudden moves in ERIS. Related stocks in the same sector appear at the bottom of the page for quick peer comparison.
For a full option chain with greeks, open-interest bias, max pain and multi-leg strategy tools, open the tick2trade terminal or visit the dedicated ERIS option chain page linked from this overview.
| Type | Details | Date |
|---|---|---|
| Results - FY26 | To consider and approve the financial results for the period ended Jun 30, 2026 | 29 Jul 2026 |
| Results - FY26 | To consider and approve the financial results for the period ended March 31, 2026 and dividend | 20 May 2026 |
| Results - FY25 | To consider and approve the financial results for the period ended December 31, 2025 | 13 Feb 2026 |
| Other | To consider issuance of equity shares of the Company by way of a preferential issue | 24 Nov 2025 |
| Results - FY25 | To consider and approve the financial results for the period ended September 30, 2025 | 12 Nov 2025 |
| Results - FY25 | To consider and approve the financial results for the period ended Jun 30, 2025 | 5 Aug 2025 |
| Results - FY25 | To consider and approve the financial results for the period ended March 31, 2025 | 19 May 2025 |
Tick2trade is a brand/platform owned and operated by Besseggen InfoTech LLP, a SEBI Registered Stock Broker holding Registration No: INZ000213450, Member of NSE (Member Code: 90155) and BSE (Member Code: 6722). Investment in securities market are subject to market risks; read all related documents carefully before investing.